This week, there are 10 drugs in the patent and exclusivity list. They are: - SUCAMPO PHARMA AMERICAS LLC's AMITIZA, containing active ingredient LUBIPROSTONE - GENENTECH INC's ERIVEDGE, containing active ingredient VISMODEGIB - GE HEALTHCARE's VIZAMYL, containing active ingredient FLUTEMETAMOL F-18 - AVERITAS PHARMA INC's QUTENZA, containing active ingredient CAPSAICIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's PRADAXA, containing active ingredient DABIGATRAN ETEXILATE MESYLATE - BAYER HEALTHCARE PHARMACEUTICALS INC's KERENDIA, containing active ingredient FINERENONE - VERTEX PHARMACEUTICALS INC's ORKAMBI, containing active ingredient IVACAFTOR; LUMACAFTOR - CURIUM US LLC's DETECTNET, containing active ingredient COPPER CU-64 DOTATATE - RIGEL PHARMACEUTICALS INC's GAVRETO, containing active ingredient PRALSETINIB - ASTELLAS PHARMA US INC's CRESEMBA, containing active ingredient ISAVUCONAZONIUM SULFATE Read More

Compounds with CAS RN 2097133-17-8, CAS RN 2778223-52-0 and CAS RN 35277-02-2 can be used to synthesize Read More

IntroductionPralsetinib, an innovative cancer-fighting drug, has been making significant strides in targeted oncology therapy—specifically against non-small cell lung cancer (NSCLC) with RET gene alterations. Pralsetinib's remarkable efficacy and ability to provide targeted treatment for cancer make Read More